CYBB and neurodegenerative disease: The clinical significance of Nox2 activation in aging-associated microgliosis and inflammation was examined using post-mortem midbrain tissues (including the hippocampus and the VTA) of human adults at young (25–38 years old) and old age (61–85 years old) without diagnosed neurodegenerative diseases.